Mackenzie Financial Corp Ultragenyx Pharmaceutical Inc. Transaction History
Mackenzie Financial Corp
- $71.6 Billion
- Q2 2025
A detailed history of Mackenzie Financial Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 19,160 shares of RARE stock, worth $662,936. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,160
Previous 18,658
2.69%
Holding current value
$662,936
Previous $675,000
3.11%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RARE
# of Institutions
362Shares Held
88.2MCall Options Held
3.64MPut Options Held
2.24M-
Vanguard Group Inc Valley Forge, PA10.2MShares$353 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$194 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$136 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$99.9 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.77MShares$95.9 Million1.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.42B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...